Company profile for NewAmsterdam Pharma

NEW Drugs in Dev.: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, choleste...
Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Gooimeer 2-35 1411 DC Naarden The Netherlands
Telephone
Telephone
+31 (0) 35 206 2971
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/01/09/3216046/0/en/NewAmsterdam-Pharma-Highlights-2025-Achievements-and-Outlines-2026-Strategic-Priorities.html

GLOBENEWSWIRE
09 Jan 2026

https://www.globenewswire.com/news-release/2026/01/05/3213172/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
05 Jan 2026

https://www.globenewswire.com/news-release/2025/12/05/3200971/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/11/25/3194271/0/en/NewAmsterdam-Pharma-to-Participate-at-Upcoming-Investor-Conferences-in-December.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183949/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181391/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-Third-Quarter-Financial-Results.html

GLOBENEWSWIRE
05 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty